Literature DB >> 19840203

Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule.

E Sendagorta1, P Herranz, M Feito, P Ramírez, U Floristán, R Feltes, D M Benito, M Casado.   

Abstract

BACKGROUND/AIM: Extramammary Paget's disease (EMPD) is an intraepidermal adenocarcinoma of apocrine gland-bearing skin. Although surgery remains the mainstay of treatment, loss of tissue function and high recurrence rates have been reported. Recently, topical Imiquimod has been shown as a safe and effective treatment option for extramammary Paget's disease.
METHODS: Three patients diagnosed of EMPD of the vulva were treated with a daily application of 5% Imiquimod cream for three weeks, followed by an every other day application for an additional three weeks.
RESULTS: Complete clinical and histological remission of the disease was achieved in the three patients. Mild irritation and tenderness were observed as the only side effects.
CONCLUSION: Based on our results, we consider that Imiquimod cream is a safe and effective therapeutic option for the treatment of vulvar EMPD. These promising results warrant further studies to determine the real efficacy and safety of Imiquimod 5% cream for the treatment of this uncommon disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840203     DOI: 10.1111/j.1468-3083.2009.03451.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

1.  Treatment of vulvar Paget disease with topical imiquimod: a case report and review of the literature.

Authors:  Laurence Feldmeyer; Katrin Kerl; Jivko Kamarashev; Pierre de Viragh; Lars E French
Journal:  J Dermatol Case Rep       Date:  2011-09-21

Review 2.  Effects of imiquimod on vulvar Paget's disease: a systematic review of literature.

Authors:  Hiroko Machida; Aida Moeini; Lynda D Roman; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2015-07-17       Impact factor: 5.482

3.  Clinical treatment of vulvar Paget's disease: a case report.

Authors:  Cristina Anton; Arthur Vicentini da Costa Luiz; Filomena Marino Carvalho; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

5.  Interventions for the treatment of Paget's disease of the vulva.

Authors:  Katharine A Edey; Ernest Allan; John B Murdoch; Susan Cooper; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

6.  Two cases of Paget's disease of scrotum in biological brothers.

Authors:  Dapang Rao; Haibo Zhu; Kaiyuan Yu; Haifeng Yu; Liping Xie
Journal:  Ther Clin Risk Manag       Date:  2015-05-27       Impact factor: 2.423

7.  Extra Mammary Paget's Disease: A Rare Case Report.

Authors:  Vidyadhar R Sardesai; Trupti D Agarwal; Sarita P Sakhalkar
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

8.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.